In Vitro antimalarial activity and drug interactions of fenofibric acid

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2814-2818

  Wong, Rina P M ^a   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ATORVASTATIN; CHLOROQUINE; CLOFIBRATE; DIHYDROARTEMISININ; FENOFIBRIC ACID; GEMFIBROZIL; ISOTOPE;

ANTIMALARIAL ACTIVITY; ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; METABOLITE; MICROTECHNOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; DRUG INTERACTIONS; FENOFIBRATE; HUMANS; PLASMODIUM FALCIPARUM;

EID: 84861152021     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05076-11     Document Type: Article

References (37)

1. Arakawa R, Tamehiro N, Nishimaki-Mogami T, Ueda K, Yokoyama S. 2005. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor- dependent manner. Arterioscler. Thromb. Vasc. Biol. 25:1193-1197. (Pubitemid 40776608)
2. Berenbaum MC. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122-130. (Pubitemid 8289152)
3. Bhavesh D, Shah S. 2009. Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. Biomed. Chromatogr. 23:922-928.
4. Boggild AK, et al. 2009. Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 49:841- 849.
5. Budd A, et al. 2007. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob. Agents Chemother. 51:2965-2968. (Pubitemid 47206237)
6. Butcher GA, Sinden RE. 2003. Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro. Am. J. Trop. Med. Hyg. 68:111-114. (Pubitemid 38234858)
7. Canfield CJ, Pudney M, Gutteridge WE. 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp. Parasitol. 80:373-381.
8. Carrara VI, et al. 2009. Changes in the treatment responses to artesunatemefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4:e4551.
9. Clark CJ, et al. 2005. Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. Infect. Immun. 73:5249-5251. (Pubitemid 41105691)
10. Clark IA, Alleva LM. 2009. Is human malarial coma caused, or merely deepened, by sequestration? Trends Parasitol. 25:314-318.
11. Clark IA, Alleva LM, Budd AC, Cowden WB. 2008. Understanding the role of inflammatory cytokines in malaria and related diseases. Travel Med. Infect. Dis. 6:67- 81.
12. Davis TM, et al. 2011. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 54:280-290.
13. Derosa G, et al. 2009. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr. Med. Res. Opin. 25:1973-1983.
14. Desager JP, Horsmans Y, Vandenplas C, Harvengt C. 1996. Pharmaco-dynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 124(Suppl):S65-S73.
15. Desjardin RE, Canfield Haynes CJ, Chulay DJD. 1979. Quantitative assessment of antimalarial activity in vitro by semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710-718.
16. Dondorp AM, et al. 2010. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol. 8:272-280.
17. Dubey S, et al. 2010. Rapid, sensitive and validated ultra-performance liquid chromatography/mass spectrometric method for the determination of fenofibric acid and its application to human pharmacokinetic study. E-J. Chem. 7:25-36.
18. Edstein MD, et al. 2005. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob. Agents Chemother. 49:4421-4422. (Pubitemid 41401005)
19. Ehrhardt M, Lindenmaier H, Burhenne J, Haefeli WE, Weiss J. 2004. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem. Pharmacol. 67:285-292.
20. Fivelman QL, Adagu IS, Warhurst DC. 2004. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob. Agents Chemother. 48: 4097-4102. (Pubitemid 39434861)
21. Jaye M, Duverger N, Searfoss G, Minnich A. November 2003. Therapeutic uses of PPAR mediators. U.S. patent 20030220373A1.
22. Karl S, Wong RP, St Pierre TG, Davis TM. 2009. A comparative study of a flow-cytometry-based assessment of in vitro Plasmodium falciparum drug sensitivity. Malar. J. 8:294 -304.
23. Keating GM, Ormrod D. 2002. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 62:1909 -1944.
24. Keech A, et al. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849 -1861.
25. Kirchgassler KU, Schmitz H, Bach G. 1998. Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200 mg in a drug monitoring programme involving 9884 patients with dyslipidaemia. Clin. Drug Invest. 15:197-204. (Pubitemid 28163746)
26. Lambros C, Vanderberg JP. 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:418-420. (Pubitemid 10222999)
27. McQuistion TE. 1979. Effect of temperature and clofibrate on Plasmodium berghei infection in mice. Am. J. Trop. Med. Hyg. 28:12-14. (Pubitemid 9111786)
28. Miller DB, Spence JD. 1998. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 34:155-162. (Pubitemid 28077673)
29. Nakornchai S, Konthiang P. 2006. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrugresistant Plasmodium falciparum in vitro. Acta Trop. 100:185-191. (Pubitemid 46176762)
30. Parquet V, et al. 2009. Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 53:2248-2252.
31. Pradines B, et al. 2007. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob. Agents Chemother. 51:2654-2655. (Pubitemid 47047361)
32. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403:906-909. (Pubitemid 30130994)
33. Teja-Isavadharm P, et al. 2004. Plasmodium falciparum-based bioassay for measurement of artemisinin derivatives in plasma or serum. Antimicrob. Agents Chemother. 48:954-960. (Pubitemid 38280349)
34. Wong R, Davis TM. 2009. Statins as potential antimalarial drugs: low relative potency and lack of synergy with conventional antimalarial drugs. Antimicrob. Agents Chemother. 53:2212-2214.
35. Wong RP, et al. 2011. Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob. Agents Chemother. 55:1194 -1198.
36. Wongsrichanalai C, Meshnick SR. 2008. Declining artesunatemefloquine efficacy against falciparum malaria on the Cambodia- Thailand border. Emerg. Infect. Dis. 14:716 -719.
37. Zhu T, Ansquer JC, Kelly MT, Sleep DJ, Pradhan RS. 2010. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. J. Clin. Pharmacol. 50:914 -921.